Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report

Capella,Mariana Pilon; Fallah,Parvaneh; Basik,Mark

doi:10.3892/ol.2024.14415

Personalized circulating tumor DNA response to local radiotherapy in a patient with an early lobular breast cancer: A case report

Authors:
- Mariana Pilon Capella
- Parvaneh Fallah
- Mark Basik
View Affiliations

Affiliations: Department of Medicine and Oncology, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University Montreal, Montreal, QC H3T 1E2, Canada, Division of Oncology, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University Montreal, Montreal, QC H3T 1E2, Canada
Published online on: April 25, 2024 https://doi.org/10.3892/ol.2024.14415
Article Number: 282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of circulating tumor DNA (ctDNA) in the plasma of cancer patients is emerging as a very sensitive and specific prognostic biomarker. Previous studies with ctDNA have focused on the ability of ctDNA detection to predict micrometastatic and eventual clinical metastatic relapse. There are few data on the role of ctDNA in monitoring response to local therapy. The present study reports the case of a patient with early‑stage lobular breast cancer, with a detectable ctDNA test which resolved with local radiotherapy to the breast. This case suggests that ctDNA is sensitive enough to detect the response of minimal residual disease, localized in the breast, to radiation therapy, and thus may assist in providing indications for local breast cancer treatment.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D and Layman RM: Invasive lobular carcinoma: An understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 193:253–264. 2022. View Article : Google Scholar : PubMed/NCBI
3	Thomas M, Kelly ED, Abraham J and Kruse M: Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 46:121–132. 2019. View Article : Google Scholar : PubMed/NCBI
4	Wilson N, Ironside A, Diana A and Oikonomidou O: Lobular breast cancer: A review. Front Oncol. 10:5913992021. View Article : Google Scholar : PubMed/NCBI
5	Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, Tozbikian G, Williams N, Majumder S and Ramaswamy B: Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist. 26:e943–e953. 2021. View Article : Google Scholar : PubMed/NCBI
6	Biglia N, Maggiorotto F, Liberale V, Bounous VE, Sgro LG, Pecchio S, D'Alonzo M and Ponzone R: Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol. 39:455–460. 2013. View Article : Google Scholar : PubMed/NCBI
7	Choi YJ, Shin YD and Song YJ: Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer. World J Surg Oncol. 14:1262016. View Article : Google Scholar : PubMed/NCBI
8	Giannakeas V, Sopik V and Narod SA: Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw Open. 1:e1811002018. View Article : Google Scholar : PubMed/NCBI
9	Boyages J and Baker L: Evolution of radiotherapy techniques in breast conservation treatment. Gland Surg. 7:5762018. View Article : Google Scholar : PubMed/NCBI
10	Tsai CJ, Huang HY, Chen FM, Yang YH, Chen LC and Hsieh KP: Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ. PLoS One. 17:e02629342022. View Article : Google Scholar : PubMed/NCBI
11	Mills MN, Russo NW, Fahey M, Nanda RH, Raiker S, Jastrzebski J, Stout LL, Wilson JP, Altoos TA, Allen KG, et al: Increased risk for ipsilateral breast tumor recurrence in invasive lobular carcinoma after accelerated partial breast irradiation brachytherapy. Oncologist. 26:e1931–e1938. 2021. View Article : Google Scholar : PubMed/NCBI
12	Sanz-Garcia E, Zhao E, Bratman SV and Siu LL: Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. Sci Adv. 8:eabi86182022. View Article : Google Scholar : PubMed/NCBI
13	Zavarykina TM, Lomskova PK, Pronina IV, Khokhlova SV, Stenina MB and Sukhikh GT: Circulating tumor DNA is a variant of liquid biopsy with predictive and prognostic clinical value in breast cancer patients. Int J Mol Sci. 24:170732023. View Article : Google Scholar : PubMed/NCBI
14	Arisi MF, Dotan E and Fernandez SV: Circulating tumor DNA in precision oncology and its applications in colorectal cancer. Int J Mol Sci. 23:44412022. View Article : Google Scholar : PubMed/NCBI
15	Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5:1124–1131. 2019. View Article : Google Scholar : PubMed/NCBI
16	Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bertlett JMS, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
17	D'Orsi C, Bassett L and Feig S: Breast imaging reporting and data system (BI-RADS). Breast Imaging Atlas. 4th edition. American College of Radiology; Reston, VA, USA: pp. 29–47. 2018
18	Amin MD, Gress DM, Meyer Vega LR, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK and Compton CC; American Joint Committee on Cancer (AJCC), : AJCC cancer staging manual. 8th edition. Springer; New York, NY, USA: pp. 10322017
19	Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D and van Westen D: Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 7:1034–1047. 2015. View Article : Google Scholar : PubMed/NCBI
20	Vlataki K, Antonouli S, Kalyvioti C, Lampri E, Kamina S, Mauri D, Harissis HV and Magklara A: Circulating tumor DNA in the management of early-stage breast cancer. Cells. 12:15732023. View Article : Google Scholar : PubMed/NCBI
21	Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al: Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 32:229–239. 2021. View Article : Google Scholar : PubMed/NCBI
22	Fiste O, Liontos M, Koutsoukos K, Terpos E, Dimopoulos MA and Zagouri F: Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: A narrative review. Ann Transl Med. 8:16032020. View Article : Google Scholar : PubMed/NCBI
23	Adejolu M, Huo L, Rohren E, Santiago L and Yang WT: False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol. 198:W304–W314. 2012. View Article : Google Scholar : PubMed/NCBI
24	Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al: Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 7:302ra1332015. View Article : Google Scholar : PubMed/NCBI
25	Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, et al: Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J Clin Oncol. 40:2408–2419. 2022. View Article : Google Scholar : PubMed/NCBI
26	Magbanua MJM, van't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, et al: Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: The I-SPY SURMOUNT study. Breast Cancer Res Treat. 198:383–390. 2023. View Article : Google Scholar : PubMed/NCBI
27	Cavallone L, Aguilar-Mahecha A, Lafleur J, Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E, Majewski J, et al: Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci Rep. 10:147042020. View Article : Google Scholar : PubMed/NCBI
28	Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, et al: Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 25:4255–4263. 2019. View Article : Google Scholar : PubMed/NCBI
29	Cailleux F, Agostinetto E, Lambertini M, Rothé F, Wu HT, Balcioglu M, Kalashnikova E, Vincent D, Viglietti G, Gombos A, et al: Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis Oncol. 6:e22001482022. View Article : Google Scholar : PubMed/NCBI
30	Lin PH, Wang MY, Lo C, Tsai LW, Yen TC, Huang TY, Huang WC, Yang K, Chen CK, Fan SC, et al: Circulating tumor DNA as a predictive marker of recurrence for patients with stage II–III breast cancer treated with neoadjuvant therapy. Front Oncol. 11:7367692021. View Article : Google Scholar : PubMed/NCBI
31	Lee TH, Kim H, Kim YJ, Park WY, Park W, Cho WK and Kim N: Implication of pre- and post-radiotherapy ctDNA dynamics in patients with residual triple-negative breast cancer at surgery after neoadjuvant chemotherapy: Findings from a prospective observational study. Cancer Res Treat. Nov 10–2023.(Epub ahead of print).